The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs

被引:30
作者
Huskey, SEW
Dean, BJ
Doss, GA
Wang, Z
Hop, CECA
Anari, R
Finke, PE
Robichaud, AJ
Zhang, MH
Wang, B
Strauss, JR
Cunningham, PK
Feeney, WP
Franklin, RB
Baillie, TA
Chiu, SHL
机构
[1] Merck Res Labs, Dept Drug Metab, Rahway, NJ 07065 USA
[2] Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA
[3] Merck Res Labs, Dept Comparat Med, Rahway, NJ 07065 USA
关键词
D O I
10.1124/dmd.32.2.246
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The absorption, metabolism, and excretion of [C-14] aprepitant, a potent and selective human substance P receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting, was evaluated in rats and dogs. Aprepitant was metabolized extensively and no parent drug was detected in the urine of either species. The elimination of drug-related radioactivity, after i.v. or p.o. administration of [C-14] aprepitant, was mainly via biliary excretion in rats and by way of both biliary and urinary excretion in dogs. Aprepitant was the major component in the plasma at the early time points ( up to 8 h), and plasma metabolite profiles of aprepitant were qualitatively similar in rats and dogs. Several oxidative metabolites of aprepitant, derived from N-dealkylation, oxidation, and opening of the morpholine ring, were detected in the plasma. Glucuronidation represented an important pathway in the metabolism and excretion of aprepitant in rats and dogs. An acid-labile glucuronide of [C-14] aprepitant accounted for similar to 18% of the oral dose in rat bile. The instability of this glucuronide, coupled with its presence in bile but absence in feces, suggested the potential for enterohepatic circulation of aprepitant via this conjugate. In dogs, the glucuronide of [C-14] aprepitant, together with four glucuronides derived from phase I metabolites, were present as major metabolites in the bile, accounting collectively for similar to 14% of the radioactive dose over a 4- to 24-h period after i.v. dosing. Two very polar carboxylic acids, namely, 4- fluoro-alpha-hydroxybenzeneacetic acid and 4- fluoro-alpha-oxobenzeneacetic acid, were the predominant drug-related entities in rat and dog urine.
引用
收藏
页码:246 / 258
页数:13
相关论文
共 27 条
[1]   Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK1 receptor antagonist [J].
Ballard, TM ;
Sänger, S ;
Higgins, GA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 412 (03) :255-264
[2]   The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist [J].
Beattie, DT ;
Beresford, IJM ;
Connor, HE ;
Marshall, FH ;
Hawcock, AB ;
Hagan, RM ;
Bowers, J ;
Birch, PJ ;
Ward, P .
BRITISH JOURNAL OF PHARMACOLOGY, 1995, 116 (08) :3149-3157
[3]   ANTIEMETIC PROFILE OF A NONPEPTIDE NEUROKININ-NK(1) RECEPTOR ANTAGONIST, CP-99,994, IN FERRETS [J].
BOUNTRA, C ;
BUNCE, K ;
DALE, T ;
GARDNER, C ;
JORDAN, C ;
TWISSELL, D ;
WARD, P .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 249 (01) :R3-R4
[4]   Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone [J].
Campos, D ;
Pereira, JR ;
Reinhardt, RR ;
Carracedo, C ;
Poli, S ;
Vogel, C ;
Martinez-Cedillo, J ;
Erazo, A ;
Wittreich, J ;
Eriksson, LO ;
Carides, AD ;
Gertz, BJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1759-1767
[5]   Anxiolytic actions of the substance P (NK1) receptor antagonist L-760735 and the 5-HT1A agonist 8-OH-DPAT in the social interaction test in gerbils [J].
Cheeta, S ;
Tucci, S ;
Sandhu, J ;
Williams, AR ;
Rupniak, NMJ ;
File, SE .
BRAIN RESEARCH, 2001, 915 (02) :170-175
[6]   Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis [J].
Cocquyt, V ;
Van Belie, S ;
Reinhardt, RR ;
Decramer, MLA ;
O'Brien, M ;
Schellens, JHM ;
Borms, M ;
Verbeke, L ;
Van Aelst, F ;
De Smet, M ;
Carides, AD ;
Eldridge, K ;
Gertz, BJ .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (07) :835-842
[7]  
DEAN B, 2000, DRUG METAB REV, V32, P261
[8]   Potential of substance P antagonists as antiemetics [J].
Diemunsch, P ;
Grélot, L .
DRUGS, 2000, 60 (03) :533-546
[9]   Broad spectrum antiemetic effects of CP-122,721, a tachykinin NK1 receptor antagonist, in ferrets [J].
Gonsalves, S ;
Watson, J ;
Ashton, C .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 305 (1-3) :181-185
[10]   Evaluation of PD154075, a tachykinin NK1 receptor antagonist, in a rat model of postoperative pain [J].
Gonzalez, M ;
Field, MJ ;
Holloman, EF ;
Hughes, J ;
Oles, RJ ;
Singh, L .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 344 (2-3) :115-120